⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
prnewswire.com
IBRX
IBRX Lead Plaintiff Deadline is May 26, 2026 - Injured Stockholders Should Contact Robbins LLP for Information About Their Rights Against ImmunityBio, Inc
accessnewswire.com
IBRX
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
globenewswire.com
IBRX
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
prnewswire.com
IBRX
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
globenewswire.com
IBRX
IBRX Deadline Alert: The Gross Law Firm Reminds ImmunityBio, Inc. (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
prnewswire.com
IBRX
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
businesswire.com
IBRX
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
IBRX
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky
globenewswire.com
IBRX
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
accessnewswire.com
IBRX